Sadly our Kit @Diamondtrees11 died on Monday 7th May. Her husband Phillip contacted us with the tragic news. We didn’t meet Kit but she was an integral part of METUPUK
In September last year, one of our Trustees Louise Furneaux died from metastatic breast cancer. She was a valued member of METUPUK and was our most recently appointed trustee. She
Birthday and cancerversaries became bittersweet as I was dealing with the realities of cancer, the side effects, the constant fear of the unknown, the helplessness, the indignity of losing who you are, who you were, even things you take for granted like walking up your own stairs or getting out the bath (because the treatment has made you weak).
And so, I feel with every year I am living with MBC, with every new treatment and with every progression, I am like a china doll. Leaving broken pieces of me behind.
“As long as you are breathing, there is more right with you than there is wrong…..”
METUPUK historically maintained their own in-house clinical trial database for metastatic trials in the UK as there was no one source that contained them all. It used the key sites used across the UK; Cancer Research UK, Be Part of Research, ISRCTN and ClinicalTrials.gov.
Leaping forward to 2022, surely by now one of them must be THE accurate, easily searchable source of breast cancer trials? If not, how do our oncologists quickly and accurately find the best trials for their metastatic patients?
And where do patients start when looking for a metastatic trial themselves?
METUPUK welcomes the approval of Piqray (alpelisib) plus fulvestrant for the treatment of hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced breast cancer.
Piqray is an exciting new cancer medicine because it is the first targeted treatment option for advanced breast cancer that has a PIK3CA mutation.
METUPUK are delighted that NICE has accepted Trodelvy (sacituzumab govitecan) for routine use on the NHS in England for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior lines of systemic therapies. This follows on from the decision to approve Trodelvy in NHS Scotland in March 2022. Wales and Northern Ireland normally follow decisions by NHS England and we hope that Trodelvy will be made available to every patient who is eligible without delay.
Have you ever wondered what the relationship is like between primary and secondary breast cancer patients when they are talking about cancer?
We’ve put 4 of our MetUpUK members on a zoom call to chat it out – Mary and Laura have secondary cancer and Helen and Emily have had primary breast cancer.
Laura has been living with metastatic breast cancer for 14.5 years, and Nina was diagnosed less than a year ago.
They have been friends since they were teenagers.
Join them as they chat about finding out their cancer was incurable.
31 life size figures of women are now set to tour the UK as an interactive campaign to raise awareness of issues surrounding secondary breast cancer after a small residency with the support of The Corn Exchange in Manchester.